Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):436–440. doi: 10.1054/bjoc.1999.0939

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

P J Beale 1, P Rogers 1, F Boxall 1, S Y Sharp 1, L R Kelland 1
PMCID: PMC2363292  PMID: 10646901

Abstract

The expression of the BCL-2 family proteins, BCL-2, BAX, BCLXLand BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCLXLand BAK levels did not correlate with sensitivity, there was a statistically significant inverse correlation (r = –0.81;P = 0.002) between growth inhibition by cisplatin and BCL-2 levels. In sublines possessing acquired resistance to various platinum-based drugs or across a panel of human ovarian carcinoma xenografts, there was no consistent pattern of BCL-2 expression. Two relatively sensitive lines (A2780 and CH1) have been stably transfected with bcl-2 and bclXLrespectively and two relatively resistant lines (A2780cisR and SKOV-3) stably transfected with bax. Overexpression of BCL-2 in A2780 cells led to resistance to cisplatin compared to the vector control when assayed at 48 h post-drug incubation but a significant increase in sensitivity at 96 h. Relative rates of apoptosis at 48- and 96-h post-cisplatin exposure mirrored the growth inhibition. There was no significant difference in sensitivity of the pair of lines by clonogenic assay. No significant changes in chemosensitivity to a variety of DNA-damaging or tubulin-interactive agents were observed in the remaining transfected lines. Taken together, these results suggest that, in human ovarian carcinoma cells, high BCL-2 levels (either naturally occurring or through gene transfection) confers a trend towards sensitivity not resistance to platinum drugs. © 2000 Cancer Research Campaign

Keywords: platinum, BCL-2, ovarian carcinoma, resistance

Full Text

The Full Text of this article is available as a PDF (72.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dive C., Hickman J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer. 1991 Jul;64(1):192–196. doi: 10.1038/bjc.1991.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eliopoulos A. G., Kerr D. J., Herod J., Hodgkins L., Krajewski S., Reed J. C., Young L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995 Oct 5;11(7):1217–1228. [PubMed] [Google Scholar]
  3. Herod J. J., Eliopoulos A. G., Warwick J., Niedobitek G., Young L. S., Kerr D. J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996 May 1;56(9):2178–2184. [PubMed] [Google Scholar]
  4. Holford J., Sharp S. Y., Murrer B. A., Abrams M., Kelland L. R. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer. 1998;77(3):366–373. doi: 10.1038/bjc.1998.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jones M., Siracky J., Kelland L. R., Harrap K. R. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br J Cancer. 1993 Jan;67(1):24–29. doi: 10.1038/bjc.1993.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones N. A., Turner J., McIlwrath A. J., Brown R., Dive C. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol. 1998 May;53(5):819–826. [PubMed] [Google Scholar]
  7. Kelland L. R., Jones M., Abel G., Valenti M., Gwynne J., Harrap K. R. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother Pharmacol. 1992;30(1):43–50. doi: 10.1007/BF00686484. [DOI] [PubMed] [Google Scholar]
  8. Kelland L. R., Mistry P., Abel G., Loh S. Y., O'Neill C. F., Murrer B. A., Harrap K. R. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 1992 Jul 15;52(14):3857–3864. [PubMed] [Google Scholar]
  9. Lock R. B., Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 1996 Sep 1;56(17):4006–4012. [PubMed] [Google Scholar]
  10. Ormerod M. G., O'Neill C., Robertson D., Kelland L. R., Harrap K. R. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol. 1996;37(5):463–471. doi: 10.1007/s002800050413. [DOI] [PubMed] [Google Scholar]
  11. Yin D. X., Schimke R. T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 1995 Nov 1;55(21):4922–4928. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES